Global Hematological Malignancies Market: Snapshot

Hematological malignancies, commonly known as hematological cancer, is registering a widespread prevalence across the world. According to the National Cancer Institute, hematological cancer is the fifth most commonly occurring cancer, globally, and is the second prominent reason behind the cancer death in the U.S. Researchers expect the incidence of hematological malignancies to increase further in the coming years, which will result in the growing need for its treatment, impacting the global hematological malignancies market greatly.

The opportunity in the worldwide market for hematological malignancies, which stood at US$27.4 bn in 2015, is likely to expand at a CAGR of 7.50% during the period from 2016 to 2024 and reach a value of US$51.9 bn by 2024.

The rich product pipeline and the improvement in the reimbursement scenario are likely to drive the growth of the market for hematological malignancies treatment, worldwide, in the near future. Moreover, the rising trend of patent protection is also expected to boost this market considerably in the coming years.

hematological malignancies market

 

Demand for Immunotherapy to Remain Strong

Immunotherapy, chemotherapy, and targeted therapy are the three most common treatment methods for hematological malignancies. Among these, immunotherapy led the demand in 2015 with a share of 41.3% in the overall market. The efficiency of immunotherapy, coupled with a lower risk of side effects, has influenced its demand considerably over the last few years.

Going forward, blockbuster drugs, such as Pomalyst, Rituxan, and Revlimid, are impacting the demand for immunotherapy positively and are expected to continue doing do throughout the forecast period, leading to a substantial rise in the immunotherapy segment. Targeted therapy is also anticipated to exhibit promising growth in the near future on account of the massive investments made for the development of targeted therapy products.

Presence of Advanced Healthcare Infrastructure to Ensure Dominance of North America

The worldwide market for hematological malignancies stretches across Asia Pacific, North America, Europe, the Middle East and Africa, and Latin America. Supported by the presence of an advanced medical and healthcare infrastructure, North America market for hematological malignancies has been leading the overall market. The growing prevalence of hematological cancer, the rising awareness level of people, and the availability of modern diagnostic technologies are expected to reflect positively on the demand for hematological malignancies therapeutics in the coming years, ensuring the dominance of this regional market.

Apart from this, Asia Pacific is also projected to experience steady growth in the demand for hematological malignancies therapeutics over the next few years. The increasing incidence of blood cancer-related mutation diagnostic cases, rising count of government-supported healthcare programs, and the imminent launch of novel drugs is expected to boost the Asia Pacific market for hematological malignancies during the forecast period. Latin America and the Middle East and Africa are anticipated to offer lucrative growth prospects to market players in the years to come due to the availability of untapped opportunities in abundance.

AbbVie Inc., Bristol-Myers Squibb Co., Celgene Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Johnson & Johnson, Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. are some of the leading players in the global market for hematological malignancies.

Expanding Investments and Rising Cancer Cases to Bring Immense Growth Prospects for the Hematological Malignancies Market

The growing prevalence of cancer across the world has led to a large number of fatalities. The expanding prevalence of cancer-related cases is leading to the innovation and development of new drugs and treatment types. Diverse types of drugs and treatment options are available for various cancer types. Hematological cancer or hematological malignancy is one of the most prominent cancer types that need to be tackled effectively. Thus, all these factors will increase the growth rate of the hematological malignancies market between 2016 and 2024.

  • Hematological malignancies start in the cells of blood-developing tissues, such as the bone marrow or the cells of the immune system. They also affect the lymph nodes. The alarming rate of the increase in hematological cancer cases will serve as a prominent growth indicator for the hematological malignancies market. Furthermore, the growing number of fatalities due to hematological malignancies is also urging many pharmaceutical companies to produce effective drugs and treatment options.
  • Research and development activities play a vital role in the growth of the hematological malignancies market. The players in the hematological malignancies market invest extensively in these activities to discover new formulations and affordable drugs. These aspects help in increasing the revenue of the players, eventually multiplying the growth rate.
  • The investments of various firms and conglomerates in the hematological malignancies market will serve as a boon and will lead to extensive growth prospects. The mergers and acquisitions will further add extra stars of growth to the hematological malignancies market. The acquisitions and mergers help in cementing the foothold of the players in the hematological malignancies market.
  • The COVID-19 pandemic has a minimal negative impact on the growth of the hematological malignancies market. The healthcare sector was exempted from the strict lockdown restrictions which did not lead to any prominent damage to the hematological malignancies market.

Hematological Malignancies Market: Overview

This report provides in-depth region wise and country wise analysis of the hematological malignancies market. Stakeholders of this report include manufacturers of hematology cancer drugs, raw material suppliers, cancer drug processing companies, and new players planning to enter the market. It further presents qualitative and quantitative analysis of the global hematological malignancies market. Qualitative analysis comprises market dynamics, trends, product overview, and country-level market information.

Quantitative analysis includes market share held by companies in 2015, market size, and forecast for the global hematological malignancies market in major countries globally such as the U.S., Canada, Germany, France, United Kingdom, Italy, Spain, Japan, China, Brazil, Mexico, South Africa and Saudi Arabia. Market revenue is provided in terms of US$ Mn from 2014 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 for all the segments, considering 2015 as the base year. The executive summary of the report provides a snapshot of the hematological malignancies with information on leading segments, country wise market information with respect to the market size, growth rate (CAGR %), and growth factors.

The market overview section, further, comprises impact factors such as drivers, restraints, and opportunities for the global hematological malignancies market. These factors would aid the stakeholders in establishing a strong foothold in the global hematological malignancies market. Furthermore, the market overview section comprises key industry events, product overview, market attractiveness analysis and emerging trend in the hematological malignancies market. The market attractiveness analysis provides a graphical view comparing the growth and market dynamics in various segments and country wise to identify the most attractive market. Market share analysis is also provided in the competitive landscape section of the report for the year 2015 in terms of value (%)

Hematological Malignancies Market: Segmentation

The hematological malignancies market has been segmented as Disease condition type, therapy type, distribution channel and geography. Based on disease condition, the market has been segmented into leukemia, lymphoma and myeloma. Likewise, on basis of therapy the market has been categorized into chemotherapy, immunotherapy and targeted therapy. Hospital pharmacies, medical stores and e-commerce platform are included into the market by distribution channel.

Geographically, the hematological malignancies market has been categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Moreover, analysis for the major countries comprising U.S. Canada, Germany, U.K., France, Italy, Spain, Japan, China, Brazil, Mexico, South Africa and Saudi Arabia have also been provided in the report. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the hematological malignancies market in various regions has been provided in this section.

This report also includes various ups and downs about particular country or geography that has impacted the overall market globally. The report provides a detailed outline/blueprint of the hematological malignancies market globally that will assist new companies in establishing their presence and market players in expanding their market share in the market.

Companies mentioned in the report

The report concludes with the company profile section which includes company overview, financial overview, SWOT analysis, product portfolio, business strategies and recent developments for market players. The major players that are profiled in the report include AbbVie, Inc., Bristol-Myers Squibb, Celgene Corporation, F. Hoffmann-La Roche Ltd., GlaxoSmithKline, and Novartis AG.

The global hematological malignancies market has been segmented into:

  • Global Hematological Malignancies Market, by Disease Condition
    • Leukemia
    • Lymphoma
    • Myeloma
       
  • Global Hematological Malignancies Market, by Therapy
    • Chemotherapy
    • Immunotherapy
    • Targeted Therapy
       
  • Global Hematological Malignancies Market, by Distribution Channel
    • Hospital Pharmacies
    • Medical Stores
    • E-commerce Platform
       
  • Global Hematological Malignancies Market, by Geography
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • France
      • U.K.
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific (APAC)
      • Japan
      • China
      • India
      • Rest of APAC
    • Latin America (LATAM)
      • Brazil
      • Mexico
      • Rest of LATAM
    • Middle East & Africa (MEA)
      • South Africa
      • Saudi Arabia
      • Rest of MEA

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Preface
     1.1. Research Scope
     1.2. Market Segmentation
     1.3. Research Objectives
     1.4. Key Questions Answered

2. Assumptions and Research Methodology
     2.1. Report Assumptions
     2.2. Acronyms Used
     2.3. Research Methodology

3. Executive Summary
     3.1. Global Hematological malignancies Market Snapshot
     3.2. Market Opportunity Map

4. Market Overview
     4.1. Product Overview
     4.2. Key Industry Events
     4.3. Death Rate of Leukemia, by Country
     4.4. Death Rate of Cancer, by Country

5. Market Dynamics
     5.1. Drivers and Restraints Snapshot Analysis
     5.2. Drivers
     5.3. Restraints
     5.4. Opportunities
     5.5. Opportunity Analysis
     5.6. Porter’s Analysis
     5.7. Pipeline Analysis (Phase III) till 2024

6. Global Hematological Malignancies Market Analysis, by Disease Condition
     6.1. Key Findings
     6.2. Introduction
     6.3. Leukemia
     6.4. Lymphoma
     6.5. Myeloma
     6.6. Key Trends
     6.7. Market Attractiveness Analysis

7. Global Hematological Malignancies Market Analysis, by Therapy
     7.1. Key Findings
     7.2. Introduction
     7.3. Chemotherapy
     7.4. Immunotherapy
     7.5. Targeted Therapy
     7.6. Key Trends
     7.7. Market Attractiveness Analysis

8. Global Hematological Malignancies Market Analysis, by Distribution Channel
     8.1. Key Findings
     8.2. Introduction
     8.3. Hospital Pharmacies
     8.4. Medical Stores
     8.5. E-commerce Platform
     8.6. Key Trend Analysis
     8.7. Market Attractiveness Analysis

9. Global Hematological Malignancies Market Analysis, by Region
     9.1. North America
     9.2. Europe
     9.3. Asia Pacific
     9.4. Latin America
     9.5. Middle East & Africa
     9.6. Market Attractiveness Analysis

10. North America Hematological malignancies Market Analysis
     10.1. North America Hematological Malignancies Market Size Forecast, By Country, 2016-2024
     10.2. North America Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
     10.3. North America Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
     10.4. North America Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
     10.5. North America Hematological Malignancies Market Attractiveness Analysis, 2016-2024

11. Europe Hematological Malignancies Market Analysis
     11.1. Europe Hematological Malignancies Market Size Forecast, By Country, 2016-2024
     11.2. Europe Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
     11.3. Europe Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
     11.4. Europe Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
     11.5. Europe Hematological Malignancies Market Attractiveness Analysis, 2016-2024

12. Asia Pacific Hematological Malignancies Market Analysis
     12.1. Asia Pacific Hematological Malignancies Market Size Forecast, By Country, 2016-2024
     12.2. Asia Pacific Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
     12.3. Asia Pacific Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
     12.4. Asia Pacific Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
     12.5. Asia Pacific Hematological Malignancies Market Attractiveness Analysis, 2016-2024

13. Latin America Hematological Malignancies Market Analysis
     13.1. Latin America Hematological Malignancies Market Size Forecast, By Country, 2016-2024
     13.2. Latin America Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
     13.3. Latin America Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
     13.4. Latin America Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
     13.5. Latin America Hematological Malignancies Market Attractiveness Analysis, 2016-2024

14. Middle East & Africa Hematological Malignancies Market Analysis
     14.1. Middle East & Africa Hematological Malignancies Market Size Forecast, By Country, 2016-2024
     14.2. Middle East & Africa Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
     14.3. Middle East & Africa Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
     14.4. Middle East & Africa Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
     14.5. Middle East & Africa Hematological Malignancies Market Attractiveness Analysis, 2016-2024

15. Competitive Landscape
     15.1. Hematological Malignancies Market Share Analysis By Company (2015)
     15.2. Competition Matrix
             15.2.1. Teva Pharmaceutical Industries Ltd.
             15.2.2. GlaxoSmithKline plc
             15.2.3. Johnson & Johnson
             15.2.4. Bristol Myers Squibb
             15.2.5. F. Hoffmann-La Roche Ltd. 
             15.2.6. Merck & Co., Inc. 
             15.2.7. Novartis AG 
             15.2.8. Pfizer, Inc. 

16. Company Profiles
     16.1. AbbVie, Inc.
             16.1.1. Company Details
             16.1.2. Company Description
             16.1.3. Business Overview
             16.1.4. SWOT Analysis
             16.1.5. Financial Analysis
             16.1.6. Strategic Overview
     16.2. Bristol-Myers Squibb Company
             16.2.1. Company Details
             16.2.2. Company Description
             16.2.3. Business Overview
             16.2.4. SWOT Analysis
             16.2.5. Financial Analysis
             16.2.6. Strategic Overview
     16.3. Celgene Corporation
             16.3.1. Company Details
             16.3.2. Company Description
             16.3.3. Business Overview
             16.3.4. SWOT Analysis
             16.3.5. Financial Analysis
             16.3.6. Strategic Overview
     16.4. F. Hoffmann-La Roche Ltd.
             16.4.1. Company Details
             16.4.2. Company Description
             16.4.3. Business Overview
             16.4.4. SWOT Analysis
             16.4.5. Financial Analysis
             16.4.6. Strategic Overview
     16.5. GlaxoSmithKline plc
             16.5.1. Company Details
             16.5.2. Company Description
             16.5.3. Business Overview
             16.5.4. SWOT Analysis
             16.5.5. Financial Analysis
             16.5.6. Strategic Overview
     16.6. Johnson & Johnson
             16.6.1. Company Details
             16.6.2. Company Description
             16.6.3. Business Overview
             16.6.4. SWOT Analysis
             16.6.5. Financial Analysis
             16.6.6. Strategic Overview
     16.7. Novartis AG
             16.7.1. Company Details
             16.7.2. Company Description
             16.7.3. Business Overview
             16.7.4. SWOT Analysis
             16.7.5. Financial Analysis
             16.7.6. Strategic Overview
     16.8. Pfizer, Inc.
             16.8.1. Company Details
             16.8.2. Company Description
             16.8.3. Business Overview
             16.8.4. SWOT Analysis
             16.8.5. Financial Analysis
             16.8.6. Strategic Overview
     16.9. Teva Pharmaceutical Industries Ltd.
             16.9.1. Company Details
             16.9.2. Company Description
             16.9.3. Business Overview
             16.9.4. SWOT Analysis
             16.9.5. Financial Analysis
             16.9.6. Strategic Overview

List of Tables

TABLE 1 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Pipeline Molecule, till 2024
TABLE 2 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 3 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Therapy, 2016–2024
TABLE 4 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 5 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Region, 2016–2024
TABLE 6 North America Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 7 North America Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 8 North America Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024
TABLE 9 North America Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 10 Europe Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 11 Europe Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 12 Europe Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024
TABLE 13 Europe Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 14 Asia Pacific Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 15 Asia Pacific Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 16 Asia Pacific Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024
TABLE 17 Asia Pacific Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 18 Latin America Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 19 Latin America Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 20 Latin America Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024
TABLE 21 Latin America Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 22 MEA Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 23 MEA Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 24 MEA Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024

List of Figures

FIG. 1 Global Hematological Malignancies Market Value Share Analysis, by Disease Condition, 2015 and 2024
FIG. 2 Global Leukemia Market Revenue (US$ Mn), 2014–2024
FIG. 3 Global Lymphoma Market Revenue (US$ Mn), 2014–2024
FIG. 4 Global Myeloma Market, Revenue (US$ Mn), 2014–2024
FIG. 5 Hematological Malignancies Market Attractiveness Analysis, by Disease Condition, 2015
FIG. 6 Global Hematological Malignancies Market Value Share Analysis, by Therapy, 2015 and 2024
FIG. 7 Global Chemotherapy Market Revenue (US$ Mn), 2014–2024
FIG. 8 Global Immunotherapy Market Revenue (US$ Mn), 2014–2024
FIG. 9 Global Targeted Therapy Market, Revenue (US$ Mn), 2014–2024
FIG. 10 Hematological Malignancies Market Attractiveness Analysis, by Therapy, 2015
FIG. 11 Global Hematological Malignancies Market Value Share Analysis, by Distribution Channel, 2015 and 2024
FIG. 12 Global Hospital Pharmacies Market Revenue (US$ Mn), 2014–2024
FIG. 13 Global Medical Stores Market Revenue (US$ Mn), 2014–2024
FIG. 14 Global E-commerce Market, Revenue (US$ Mn), 2014–2024
FIG. 15 Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel, 2015
FIG. 16 North America Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 17 Europe Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 18 APAC Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 19 Latin America Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 20 MEA Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 21 Global Hematological Malignancies Market Attractiveness Analysis, by Region
FIG. 22 U.S. Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 23 Canada Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 24 North America Hematological Malignancies Market Attractiveness Analysis, by Country
FIG. 25 North America Hematological Malignancies Market Attractiveness Analysis, by Disease Condition
FIG. 26 North America Hematological Malignancies Market Attractiveness Analysis, by Therapy
FIG. 27 North America Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
FIG. 28 Germany Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 29 France Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 30 The U.K. Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 31 Italy Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 32 Spain Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 33 Rest of Europe Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 34 Europe Hematological Malignancies Market Attractiveness Analysis, by Country
FIG. 35 Europe Hematological Malignancies Market Attractiveness Analysis, by Disease Condition
FIG. 36 Europe Hematological Malignancies Market Attractiveness Analysis, by Therapy
FIG. 37 Europe Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
FIG. 38 Japan Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 39 China Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 40 India Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 41 Rest of APAC Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 42 Asia Pacific Hematological Malignancies Market Attractiveness Analysis, by Country
FIG. 43 Asia Pacific Hematological Malignancies Market Attractiveness Analysis, by Disease Condit
FIG. 44 Asia Pacific Hematological Malignancies Market Attractiveness Analysis, by Therapy
FIG. 45 Asia Pacific Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
FIG. 46 Brazil Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 47 Mexico Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 48 Rest of LATAM Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 49 Latin America Hematological Malignancies Market Attractiveness Analysis, by Country
FIG. 50 Latin America Hematological Malignancies Market Attractiveness Analysis, by Disease Condition
FIG. 51 Latin America Hematological Malignancies Market Attractiveness Analysis, by Therapy
FIG. 52 Latin America Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
FIG. 53 South Africa Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 54 Saudi Arabia Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 55 Rest of MEA Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 56 MEA Hematological Malignancies Market Attractiveness Analysis, by Country
FIG. 57 MEA Hematological Malignancies Market Attractiveness Analysis, by Disease Condition
FIG. 58 MEA Hematological Malignancies Market Attractiveness Analysis, by Therapy
FIG. 59 MEA Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
FIG. 60 Hematological Malignancies Market Share Analysis, by Company (2015)

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Hematological Malignancies Market